Resources

Publications XTAL has contributed to:

• RVX-297 – A Novel BD2 Selective Inhibitor of BET Bromodomains (August, 2016)
• Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects (April, 2016)
• Discovery of a New Chemical Series of BRD4 (1) Inhibitors Using Protien-Ligand Docking and Structure-Guided Design (July, 2015)
• A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy (June, 2015)
• Protein Kinases in the Era of Precision Medicine (February, 2015)
• Synthesis of Aspartame by Thermolysin: An X-Ray Structural Study (April, 2014)
• Cancer-Associated IDH1 Mutations Produce 2-Hydroxyglutarate (June, 2010)
• RVX-208, an inducer of ApoA-I in Humans, is a BET Bromodomain Antagonist (December, 2013)
• Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineering BMPs with superior agonist activity (April, 2010)
• Protein Kinases: Signature in Cancer (December, 2009)